Deutsche Bank Ag\ Tcr2 Therapeutics Inc. Transaction History

Deutsche Bank Ag\

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 11, 2022	BUY	$2.11 - $2.94 $1,527 - $2,128	724 Added 3.81%	19,706 $57,000
Q1 2022 May 13, 2022	BUY	$2.4 - $4.71 $1,106 - $2,171	461 Added 2.49%	18,982 $53,000
Q4 2021 Feb 11, 2022	SELL	$4.58 - $8.34 $101,630 - $185,064	-22,190 Reduced 54.51%	18,521 $86,000
Q3 2021 Nov 04, 2021	BUY	$8.44 - $18.35 $178,092 - $387,203	21,101 Added 107.6%	40,711 $346,000
Q2 2021 Aug 11, 2021	SELL	$16.41 - $24.71 $1.38 Million - $2.09 Million	-84,394 Reduced 81.14%	19,610 $322,000
Q1 2021 May 13, 2021	BUY	$20.38 - $34.07 $6,012 - $10,050	295 Added 0.28%	104,004 $2.3 Million
Q4 2020 Feb 16, 2021	SELL	$19.0 - $32.63 $1.43 Million - $2.45 Million	-75,012 Reduced 41.97%	103,709 $3.21 Million
Q3 2020 Nov 12, 2020	BUY	$13.1 - $20.69 $2.24 Million - $3.53 Million	170,823 Added 2162.86%	178,721 $3.63 Million
Q2 2020 Aug 13, 2020	BUY	$6.51 - $16.85 $27,537 - $71,275	4,230 Added 115.32%	7,898 $121,000
Q1 2020 May 14, 2020	SELL	$6.01 - $16.01 $1,406 - $3,746	-234 Reduced 6.0%	3,668 $28,000
Q4 2019 Feb 14, 2020	BUY	$12.17 - $17.88 $9,748 - $14,321	801 Added 25.83%	3,902 $55,000
Q3 2019 Nov 14, 2019	BUY	$10.15 - $19.53 $17,874 - $34,392	1,761 Added 131.42%	3,101 $46,000
Q2 2019 Aug 14, 2019	BUY	$13.64 - $20.97 $18,277 - $28,099	1,340 New	1,340 $18,000

Ticker TCRR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,606,400
Description
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical tria...

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

Stay updated on Deutsche Bank Ag\ with notifications on news.